Rituximab maintenance in follicular lymphoma patients

Table 1 Randomized trials comparing Rituximab-chemotherapy vs chemotherapy alone in follicular lymphoma patients

Reference	Year	Prior treatment	Treatment	No of patients	ORR	OS	PFS
Marcus et al[3,4]	2005, 2008	No	R-CVP vs CVP	321	81% vs 57% (P < 0.001)	83% vs 77% at 4-years (P = 0.029)	27 vs 7 mo ( P < 0.001) 1
Hiddeman et al[5]	2005	No	R-CHOP vs CHOP	428	96% vs 90% (P = 0.001)	95% vs 90% at 2 yrs (P =0.016)	91% vs 79% at 2 yrs ( P < 0.001)1
van Oers et al[6,7]	2006, 2010	Yes	R-CHOP vs CHOP	465	85% vs 72% (P < 0.001)	82% vs 79% at 3 years (P = 0.09)	33 vs 20 mo ( P < 0.001)
Forstpointner et al[10]	2006	Yes	R-FCM vs FCM	125	95% vs 71% (P = 0.01)	Not available2	Not available2
Herold et al[9]	2007, 2010	No	R-MCP vs MCP	358	92% vs 75% (P < 0.001)	86% vs 74% at 5 years (P = 0.02)	86 vs 35 mo ( P < 0.001)
Salles et al[8]	2000	No	R-CHVP-I vs CHVP-I	358	94% vs 85% (P < 0.001)	84% vs 79% at 5-years (P = 0.15)	53% vs 37% at 5 years (P < 0.01)

ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival;

¹ Time-to-treatment-failure;

² Data not available because of protocol design (double randomization).